Introduction
============

Oral cavity cancer is the 11th most common cancer in the world. Its incidence rate is highly correlated with exposure to tobacco, betel nut chewing, and alcohol in developing nations, and the incidence of human papillomavirus (HPV) infection in developed countries ([@ref-19]; [@ref-23]; [@ref-33]). Advanced surgical technology in oral cancer increases the survival rate, but the primary functions of the oral cavity---respiration, speech, mastication, deglutition, and appearance---are significantly compromised. Impairments include scar contracture or radiation-induced trismus, drooling, impaired mastication and deglutition with a lip or tongue defect. In the advanced stage of cancer, donor-site-related impairments often develop, such as accessory nerve shoulder dysfunction (ANSD) ([@ref-6]; [@ref-13]; [@ref-39]; [@ref-43]). The probability of shoulder dysfunction after neck dissection is as high as 70% ([@ref-7]; [@ref-13]). ANSD is manifested as impaired shoulder mobility and pain. Electromyography (EMG) studies have shown significant increase in spinal accessory nerve denervation ([@ref-14]) and decreased trapezius muscle activity after neck dissection ([@ref-20]; [@ref-27]). Though the modified radical and selective neck dissections aims to reduce the prevalence of shoulder dysfunction, a wide range of ANSD incidence rates after neck dissection have been reported ([@ref-38]; [@ref-41]).

Health-related quality of life (QoL) has been extensively studied in oral cancer survivors to identify the impact of the treatment-related morbidity and physical issues. This is used for newly diagnosed oral cancer as well as recurrence. Recent studies have demonstrated that poor oral and physical health-related QoL are found in oral cancer patients compared with the general population ([@ref-1]). Shoulder dysfunction (decreased muscle strength, range of motion \[ROM\] and pain) is associated with decreased QoL ([@ref-31]). Postoperative radiation therapy is associated with decreased global health, increased xerostomia and short term fatigue ([@ref-11]). Issues of oral function, such as swallowing, speech and social eating ensue one year or more after the reconstructive surgery. Poor role function and social function are predicted in the advanced-stage oral cancer survivors as well ([@ref-35]). In these, shoulder dysfunction, global health, oral function and social function would be the aim of address in this study.

Given the issues mentioned above, this study aims to explore changes in physical function and self-perceived QoL in consequence of an early intervention program after oral cancer reconstructive surgery. While most research focuses on a single measure of treatment outcome and its effect on QoL, we assumed that a range of treatment outcome measures would affect health-related quality of life, including symptoms, dysfunctions, and survival. Therefore, this research aims to evaluate the outcomes of an early-intervention program (i.e., progressive resistance exercise, soft-tissue massage, joint range of motion exercise, pain management and functional training) by physical examination, QoL questionnaire and return-to-work status after oral cancer reconstructive microsurgery through exploratory analyses. Through exploring the outcomes in the early and the advanced stage population eligible for surgery, the results may help develop and identify intervention guidelines and goals in the initial 6 months of treatment following neck dissection in oral cancer survivors.

Materials and Methods
=====================

This study was a single-arm preliminary pilot study. The participants were enrolled from January 2015 to June 2016. The inclusion criteria were survival after excision of oral cavity squamous cell carcinoma (SCC) with reconstructive microsurgery, and age between 20 and 65 years old. Patients are recruited through the plastic surgeon's referral. Patients were excluded if they were identified as cognitively impaired; having distant metastasis or recurrence; or unable to communicate or comprehend the questionnaires. Written informed consent and verbal trial information was provided and obtained from all participants. Informed consent for publication of identifying images of study participants was also obtained. This study was conducted in the Chang Gung Memorial Hospital in Taoyuan, Taiwan, and approved by the Chang Gung Medical Foundation Institutional Review Board (Approval No: 103-5164B, 104-2300C, 104-8154C). The authors declare that all methods were performed according to the relevant guidelines and regulations established by the oversight boards and agencies.

Interventions started early after the reconstructive microsurgery. All participants underwent each component of the intervention program, which consisted of pain management, scar management, temporomandibular joint (TMJ) exercise, shoulder and neck exercise, and functional training of the donor site and recipient site to restore oral and physical function. The intervention program was divided into three phases: (1) the early phase (within 1 month after operation), (2) the middle phase (1 to 3 months post-operation), (3) and the late phase (more than three months post-operation).

Early phase
-----------

The early phase intervention initiated at an average of 8.3 days following reconstructive surgery and lasted within one month post operation. In the early phase, the main goal was to help the participants deal with the problems suffered (i.e., pain, edema, shoulder dysfunction and strength loss, soft tissue tightness and functional limitation) as the result of the surgery. The intervention consisted were as follows: (1) Transcutaneous Electrical Stimulation was administered for 15 min. per treatment session and the intensity was adjusted to patient's tolerance to alleviate shoulder pain or soreness. (2) Gentle soft tissue mobilization and scar massage on the donor and recipient sites was performed for 15 min. per treatment session and the intensity was adjusted to patient's tolerance to prevent edema-induced stiffness. (3) To increase TMJ range of motion, the participants were guided to exercise their TMJ during the first visit and to use tongue depressors to assist in performing the TMJ exercise if needed in the following visits. (4) Active or active-assistive exercises for neck, shoulder and donor site were performed for 10 repetitions in each session. (5) The progressive shoulder resistance exercise consisted of closed-chain and open-chain exercises that were adjusted sequentially according to pain conditions ([Fig. 1](#fig-1){ref-type="fig"}). (6) In cases involving fibular osteoseptocutaneous flap harvest, big toe flexion was avoided in the initial six weeks. (7) Functional training such as transfer, ambulation, and activities of daily living (ADL) was administered before discharge from the hospital. All of these were initiated as soon as the wound condition was stable (i.e., normal capillary refill decided by the surgeon clinically.) The participants were instructed to perform self-massage and other ROM exercises hourly during waking hours and was checked using exercise diaries kept by the participants. During the period of hospitalization (average duration = 3 weeks), participants received the intervention every weekday for an average of 40 min. per treatment session. The treatment program was administered once a week after discharge from hospital.

![Scapula control exercise.\
(A--C) Anti-scapular winging exercise: bilateral hands held together and elevated to the top then placed behind the head, pulling the bilateral scapular closer. (D) Wall press exercise. (E) Wall press with scapular elevation exercise. (F) Wall press with arm clock exercise.](peerj-06-4419-g001){#fig-1}

Middle phase
------------

The middle phase lasted from 1--3 months post operation. During this phase, the goal was to focus on the impairment suffered (i.e., scar development, soft tissue tightness, shoulder joint dysfunction and strength loss, functional limitation) from the surgery or radiation therapy (RT). The participants attended the rehabilitation center for one-on-one therapy once per week. The interventions included: (1) Scar massage was employed 5 to 10 min prior to other treatment programs. (2) Soft tissue massage and joint ROM exercise as described in the early phase was implemented as well with intensity up to patient's tolerance. Once the participants felt free of shoulder pain, the training was transferred to the open-chain exercise. (3) Progressive resistance exercise (PRE) training for the open-chain exercises was administered with free weights or thera-bands 1 set of 10 repetitions in one session ([Fig. 2](#fig-2){ref-type="fig"}). In this phase, some of the participants started to receive RT, which can interfere with TMJ and oral function. (4) To maintain TMJ flexibility, conventional therapy for TMJ was maintained in these subjects. On top of that, oral function training was implemented as well. (5) Tongue and lip mobility and coordination training, and instructions on food intake were included. (6) In cases where a fibular osteoseptocutaneous flap was performed, the big toe and ankle joint were stretched in this phase to increase joint ROM and soft tissue flexibility. The training programs were evaluated and adjusted as needed during every visit. Each treatment session lasted for an average of 50 min. Participants were also instructed to perform individual home-programs on an hourly basis when awake at home. Compliance to home-programs was checked having the patients keep diaries regarding their home endeavors.

![Progressive resistance exercise (PRE) training.\
(A) Shoulder diagonal flexion with thera-band. (B) Shoulder horizontal abduction and scapulae retraction with thera-band. (C) Shoulder flexion and abduction with free weights.](peerj-06-4419-g002){#fig-2}

Late phase
----------

The late phase started more than three months post-operation. The goal in this phase was to recover the residual functions as much as possible. The interventions included were: (1) Pain and scar management with intensity up to patient's tolerance and (2) shoulder PRE programs were implemented as in the previous phase, i.e., 10 repetitions each session. (3) If microstomia was caused by the intra-oral scar contracture after RT, a microstomia splint was prescribed and intra-oral scar massage was applied. Treatments to improve oral, shoulder joint and physical functioning were performed and progressed according to individual performance. The participants attended the rehabilitation center once a week. Each treatment session lasted for 1 h during this phase. In addition to a weekly visit to the rehabilitation center, patients were asked to perform their individual home programs with hourly exercise of the TMJ and shoulder, and were also encouraged to perform physical exercise (i.e., scar massage, mouth opening exercise, shoulder-neck ROM and PRE, et al.) at least three to five times a week.

All the intervention program is based on a variety of clinical trials compiled in the review article by [@ref-16].

All the treatments were provided by three certified therapists with an average of more than 10 years of clinical experience.

Baseline data included demographic information and outcome variables taken during the 1st visit after operation. Data at one, three and six months after the operation were also included. Furthermore, return-to-work status of all subjects employed at baseline were followed at 12-month post operation through telephone interview to confirm if they are back to work.

Outcome measurements
--------------------

Demographic data including gender, age, marital status, education level, disease staging, oncology and reconstructive treatment were collected after informed consent was given. Outcome measurements included shoulder outcomes, oral health, health-related QoL and physical functions. Shoulder outcomes were evaluated according to shoulder joint ROM and muscle strength (MMT), the visual analog scale (VAS) for the assessment of shoulder pain, and the Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure for upper extremity function. Oral health was evaluated using maximum mouth opening (MMO) and diet status, which was divided into nasogastric (NG) tube feeding, liquid diet, soft diet or normal diet. Health-related QoL was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire Core Head and Neck 35 (QLQ-HN35), and using physical function evaluations. Six-minute walking distance (6MWD) and the timed up and go (TUG) tests were employed to evaluate physical function.

MMT and ROM
-----------

The strength of the rotator cuff, pectoralis muscle, deltoid, trapezius, serratus anterior, rhomboid and latissmus dorsi were evaluated according to the numerical grading system of Medical Research Council (MRC) scale. A score of 4 is the acknowledged cut-off score that demonstrates the muscle's ability to hold testing position against gravity and moderate resistance ([@ref-22]). Shoulder joint ROM was evaluated in flexion, abduction, external rotation, and internal rotation with a two-arm goniometer under standard procedures. The evaluation was terminated when any contraindications in the prone position were indicated such as breathing difficulty. Interincisor distance (IID) was collected in millimeters by a Willis gauge, in the case of healthy teeth. Maximal mouth opening (MMO) was measured by measuring the difference between the distances between the nose tip to mandible during mouth opening and mouth closing.

DASH outcome measure
--------------------

The DASH outcome measure is a self-report questionnaire and a clinical tool to measure physical function and symptoms of the upper extremity, which studies have found useful for patients after neck dissection ([@ref-7]; [@ref-9]). The disability/symptom section contains 30 items scored from 1 to 5 indicating "no difficulty" to "unable" to perform the task. At least 27 items must be completed, scores are consequently transformed into a total scale of 1--100. Higher scores indicate greater disability. A minimum clinically important difference (MCID) was used to assess the smallest perceived important change ([@ref-12]). A change score exceeding 15 points is the most accurate change score for discriminating between improved and unimproved state ([@ref-2]).

EORTC QLQ-C30 and QLQ-HN35
--------------------------

The EORTC QLQ-C30 is a questionnaire developed to evaluate the general quality of life of cancer patients. The QLQ-H&N35 is one of the disease-specific module supplements for head and neck cancer. The QLQ-H&N35, in conjunction with the QLQ-C30, is considered a reliable and valid assessment of the quality of life among patients with head and neck cancer in various different countries ([@ref-4]; [@ref-10]; [@ref-34]). The EORTC QLQ-C30 contains 30 questions and is divided into a global health scale, five functional (physical, role, cognitive, emotional, and social) scales, and nine symptom (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) scales. The EORTC QLQ-H&N35 contains 35 questions and is divided into six symptom scales (pain, swallowing, senses (taste/smell), speech, social eating, and social contact), and seven single items (impaired sexuality, teeth problems, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill). Every scale is transformed into a score ranging from 0 to 100. A higher score on the functional scale or global health scale represents a higher level of functioning or quality of life. In contrast, a higher score on the symptom scale or single item scale reflects a worse symptom or problem.

Physical functions
------------------

The 6-minute walking distance (6MWD) and the timed up and go (TUG) tests were employed to evaluate physical capacity and lower extremity function. 6MWD is a tool used to evaluate functional exercise capacity of cancer patients and has been suggested to be as valid and reliable in this context as it is in evaluating cardiopulmonary patients ([@ref-36]). The test was performed in 6 min, and the patients were asked to walk to the end and back on a 20 m walkway as fast as they can, without overexertion. The total distance was recorded in millimeters. The TUG test is a commonly used tool that is evidently based to predict functional mobility and stability in less healthy, lower-functioning adults ([@ref-37]). It measures the time in seconds to stand up from a sitting position on a chair, walk 3 m, turn, walk back, and to sit back down on the chair.

All the evaluations were conducted by a different group of two certified therapists blinded to the study, with an average 12.5 years of clinical experience.

Statistical analysis
--------------------

SPSS 20.0 was used in the data analysis with a maximum significance level set at 0.05. Independent *t*-tests were used for the analysis of continuous variables. For the categorical data, chi-squared tests or Fisher's exact tests were used to analyze differences in the independent variables of gender, marital status, educational level, breadwinner, vocation, TNM stage, neck dissection, radiation therapy, diet and donor site, while independent *t*-tests were applied to test for differences in the dependent variables of age, 6MWD and TUG. The Generalized Estimating Equations (GEE) procedure was conducted to analyze repeated measures outcome variables over time. We used the GEE model which assumed unstructured working correlation matrix. GEE has the benefit of a robust estimator, and it can overcome the limitation of missing data and adjust for correlations between observations as well. Separate models were run for each outcome variable. Bilateral shoulders were evaluated separately when bilateral neck dissections had been performed. The data were excluded if the participants had shoulder problems before the operation. Pearson correlation coefficient was used to measure the degree of association between outcome variables. Kaplan--Meier estimates were used for the survival analysis to predict the rate of return-to-work. The log rank test was conducted to compare differences in the rate of return-to-work between the early stage and advanced stage groups.

Results
=======

Study population
----------------

A total of 65 participants (60 male and five female, mean age 51.6 years) who underwent 80 neck dissections (15 subjects received bilateral neck dissections), were analyzed in this study after reconstructive microsurgery. Thirteen eligible subjects declined to enroll. The drop-out rate was 34%. The reason was decondition and fatigue caused by RT that decreased their willingness to participate in the intervention program. The CONSORT flow diagram is shown in [Fig. 3](#fig-3){ref-type="fig"}. The demographic data are summarized in [Table 1](#table-1){ref-type="table"}. A supplementary table ([Table S1](#supp-4){ref-type="supplementary-material"}) is provided to present the demographic comparison between the drop-out and the analytic groups. To explore differences in the outcomes between the early stage and the advanced stage group, we compared them with respect to all variables of interest (using group model). Apart from the disease-related variables, there were no significant differences in the demographic data of the early staged group and the advanced group.

![The CONSORT flow chart.](peerj-06-4419-g003){#fig-3}
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###### Demographic and clinical characteristics of the study participants.

![](peerj-06-4419-g005)

                                                         Early stage (*n* = 27)   Advanced stage (*n* = 38)   *p*-value
  ------------------- ---------------------------------- ------------------------ --------------------------- -----------
  Age                 50.7 ± 9.9                         51.8 ± 10.6              .660                        
  Gender              F                                  3 (11%)                  2 (5%)                      .642
                      M                                  24 (89%)                 36 (95%)                    
  Education           \<9 years                          10 (39%)                 16 (42%)                    .878
                      9--12 years                        13 (46%)                 18 (47%)                    
                      \>12 years                         4 (15%)                  4 (11%)                     
  Marriage            Single                             3 (11%)                  4 (11%)                     1.000
                      Married                            21 (78%)                 30 (79%)                    
                      Other                              3 (11%)                  4 (11%)                     
  Breadwinner         N                                  10 (37%)                 10 (27%)                    .394
                      Y                                  17 (63%)                 28 (73%)                    
  Vocation            Retired/unemployed                 1 (4%)                   7 (18%)                     .253
                      Self-employed                      7 (26%)                  8 (21%)                     
                      Professional                       3 (11%)                  2 (5%)                      
                      Administration                     2 (7%)                   1 (3%)                      
                      Service                            6 (22%)                  4 (11%)                     
                      Semi-skilled/skilleds worker       8 (30%)                  16 (42%)                    
  ND                  Right                              10 (37%)                 15 (40%)                    .002
                      Left                               16 (59%)                 9 (24%)                     
                      Bilateral                          1 (4%)                   14 (37%)                    
  Area of tumor       Buccal                             11 (41%)                 9 (24%)                     .714
                      Tongue                             6 (22%)                  11 (29%)                    
                      Mouth floor                        2 (7%)                   6 (16%)                     
                      Gum                                4 (15%)                  4 (11%)                     
                      Pharyngeal wall                    0 (0%)                   2 (5%)                      
                      Lip                                1 (4%)                   2 (5%)                      
                      Retromolar tumor                   2 (7%)                   2 (5%)                      
                      Gingival                           0 (0%)                   1 (3%)                      
                      Hard palate                        0 (0%)                   1 (3%)                      
                      Soft palate                        1 (4%)                   0 (0%)                      
  T stage             1                                  8 (30%)                  0 (0%)                      \<.001
                      2                                  19 (70%)                 11 (29%)                    
                      3                                  0 (0%)                   7 (18%)                     
                      4                                  0 (0%)                   20 (53%)                    
  N stage             0                                  27 (100%)                10 (26%)                    \<.001
                      1                                  0 (0%)                   8 (21%)                     
                      2                                  0 (0%)                   19 (50%)                    
                      3                                  0 (0%)                   1 (3%)                      
  M stage             0                                  27 (100%)                38 (100%)                   
  Radiation therapy   No                                 20 (74%)                 8 (22%)                     \<.001
                      Yes                                7 (26%)                  30 (78%)                    
  Donor site          Anterolateral thigh flap           7 (26%)                  8 (21%)                     .089
                      Fibular osteoseptocutaneous flap   1 (4%)                   9 (24%)                     
                      Other                              19 (70%)                 21 (55%)                    

Shoulder outcomes
-----------------

All participants had neck dissections, and none had a prior history of shoulder pain. With respect to shoulder ROM of the affected shoulder, only abduction showed a significant difference between six months and baseline or compared with the unaffected side during six months of the study (*p* \< .001) ([Tables 2](#table-2){ref-type="table"} and [3](#table-3){ref-type="table"}). MMT of the middle trapezius, lower trapezius and rhomboid muscles were not performed at the baseline because patients were unable to comfortably maintain a prone posture. The muscle strength of the infraspinatus, subscapularis, teres muscles, pectoralis muscles and latissmus dorsi demonstrated normal strength at the baseline and exhibited no significant differences in the subsequent tests. Apart from the upper trapezius and levator scapular which gained stability of normal strength (4.9 ± 0.3) one month post operation ([Table 2](#table-2){ref-type="table"}), the anterior and middle deltoid, trapezius, serratus anterior, rhomboid all showed significant differences in strength between the 6-month assessment compared to baseline, one month and three months, individually (*p* \< .001) ([Table 2](#table-2){ref-type="table"}). At one-month evaluation, only middle and lower trapezius scored less than 4 on the MMT scale. Other muscles attained sufficient strength to overcome some resistance and gravity. Comparison of the ratio of the shoulder outcomes of the neck dissection side and the sound side indicates that the shoulder ROM and muscle strength reached almost equivalent level to the sound side except in the middle and lower trapezius at six months of the study ([Table 3](#table-3){ref-type="table"}).
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###### Progression of ROM of shoulder joint and of MMT of scapular stabilizers.
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              Baseline   1 month   3 months   6 months   *p*-value for trend                         
  ----------- ---------- --------- ---------- ---------- --------------------- ------ ------- ------ --------
  ROM (°)                                                                                            
  Flexion     152.1      20.7      151.3      22.1       155.3                 21.3   158.9   14.2   .058
  Abduction   146.3      29.1      154.8      24.8       161.4                 14.4   165.0   16.5   \<.001
  IR          74.5       10.3      77.1       9.0        72.0                  8.7    70.8    11.3   .108
  ER          79.7       14.8      82.3       10.2       81.3                  10.0   82.2    11.2   .337
  MMT                                                                                                
  MT                               4.2        0.9        4.4                   0.7    4.8     0.4    \<.001
  MLT                              2.7        1.0        2.8                   1.1    3.4     1.3    .001
  RMM                              4.4        0.8        4.7                   0.5    4.9     0.2    \<.001
  SA          4.2        0.9       4.5        0.6        4.6                   0.7    4.9     0.4    \<.001
  LUT         4.6        0.8       4.9        0.3        4.9                   0.3    5.0     0.2    \<.001
  AD          4.4        0.7       4.7        0.5        4.8                   0.6    4.9     0.3    \<.001
  MD          4.2        0.9       4.6        0.7        4.6                   0.8    4.9     0.4    \<.001

**Notes.**

ROMrange of motionIRinternal rotationERexternal rotationMMTmanual muscle testingMTmiddle trapeziusMLTmiddle and lower trapeziusRMMrhomboid major and minorSAserratus anteriorLUTupper trapezius and levator scapularADanterior deltoid and coracobrachialisMDmiddle deltoid and supraspinatus

10.7717/peerj.4419/table-3

###### Comparison of the ratio of the shoulder joint ROM and MMT between the neck-dissection side and the sound side.
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              Baseline   1 month   3 months   6 months   *p*-value for trend                       
  ----------- ---------- --------- ---------- ---------- --------------------- ----- ------ ------ --------
  ROM                                                                                              
  Flexion     .93        .13       .92        .15        .95                   .13   .97    .05    .027
  Abduction   .87        .17       .88        .16        .93                   .06   .96    .05    \<.001
  IR          1.06       .21       1.06       .12        1.02                  .14   1.02   .13    .101
  ER          .97        .11       .99        .06        .96                   .08   .98    .07    .467
  MMT                                                                                              
  MT                               .93        .15        .94                   .10   1.00   .16    .012
  MLT                              .69        .21        .68                   .22   .76    .23    .005
  RMM                              .97        .08        .99                   .03   1.00   0.00   .025
  SA          .93        .17       .90        .14        .92                   .12   .98    .07    .240
  LUT         .94        .15       .98        .06        .99                   .04   1.00   0.00   .026
  AD          .92        .13       .94        .12        .96                   .10   .98    .06    .003
  MD          .90        .14       .92        .14        .95                   .12   .98    .09    \<.001

**Notes.**

ROMrange of motionIRinternal rotationERexternal rotation MMT manual muscle testingMTmiddle trapeziusMLTmiddle and lower trapeziusRMMrhomboid major and minorSAserratus anteriorLUTupper trapezius and levator scapularADanterior deltoid and coracobrachialisMDmiddle deltoid and supraspinatus

The average shoulder pain score on the VAS was 1.81 ± 2.28 at the baseline, and 1.09 ± 1.89 at six months. VAS scores showed no significant difference between six month and baseline. However, the pain scale measured in the self-reported quality-of-life questionnaire EORTC QLQ-C30 showed a significantly higher score at the baseline (44.9 ± 26.0) (*p* \< .001) compared with subsequent evaluations ([Table 4](#table-4){ref-type="table"}). The mean DASH score at the baseline was 34.4 ± 24.0 and significantly dropped to 17.4 ± 16.2 at 1 month (*p* \< .001), which was considered a minimum clinically important difference (MCID).

10.7717/peerj.4419/table-4

###### Overview of the EORTC QLQ-C30 scores in the whole model and group model.
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                                      Overall model   Group model                                                                                                                                       
  ------------------------ ---------- --------------- -------------------------------------------------------- --------------- -------------------------------------------------------- --------------- --------------------------------------------------------
  Global quality of life   Baseline   34.66 ± 28.88   −28.57[^\*^](#table-4fn1){ref-type="fn"}(−36.5, −20.6)   33.33 ± 27.74   −34.18[^\*^](#table-4fn1){ref-type="fn"}(−45.9, −22.4)   35.65 ± 30.05   −22.07[^\*^](#table-4fn1){ref-type="fn"}(−32.4, −11.8)
                           1m         54.94 ± 20.32   −7.19[^\*^](#table-4fn1){ref-type="fn"}(−13.4, −1.0)     56.06 ± 20.60   −10.58[^\*^](#table-4fn1){ref-type="fn"}(−18.5, −2.7)    54.17 ± 20.41   −2.69 (−11.4, 6.0)
                           3m         56.94 ± 19.75   −6.25[^\*^](#table-4fn1){ref-type="fn"}(−11.4, −1.1)     64.58 ± 20.22   −3.23 (−9.8, 3.3)                                        50.40 ± 17.09   −7.27[^\*^](#table-4fn1){ref-type="fn"}(−14.4, −0.2)
                           6m         62.33 ± 22.09   ref.                                                     67.97 ± 26.46   ref.                                                     55.93 ± 14.05   ref.
  Physical function        Baseline   62.97 ± 24.44   −21.37[^\*^](#table-4fn1){ref-type="fn"}(−27.3, −15.4)   68.89 ± 23.32   −20.01[^\*^](#table-4fn1){ref-type="fn"}(−30.1, −9.9)    58.77 ± 24.65   −21.98[^\*^](#table-4fn1){ref-type="fn"}(−28.5, −15.5)
                           1m         78.15 ± 19.44   −5.75[^\*^](#table-4fn1){ref-type="fn"}(−10.1, −1.4)     80.00 ± 16.84   −8.27[^\*^](#table-4fn1){ref-type="fn"}(−13.5, −3.0)     76.88 ± 21.22   −3.58 (−9.6, 2.4)
                           3m         81.56 ± 17.33   −2.27 (−5.8, 1.3)                                        85.79 ± 15.38   −2.38 (−6.6, 1.8)                                        77.94 ± 18.34   −2.11 (−7.6, 3.4)
                           6m         84.48 ± 15.79   ref.                                                     86.99 ± 18.97   ref.                                                     81.63 ± 11.13   ref.
  Role function            Baseline   45.38 ± 37.79   −32.18[^\*^](#table-4fn1){ref-type="fn"}(−43.4, −21.0)   48.15 ± 36.20   −33.81[^\*^](#table-4fn1){ref-type="fn"}(−48.2, −19.4)   43.42 ± 39.24   −30.04[^\*^](#table-4fn1){ref-type="fn"}(−46.8, −13.3)
                           1m         67.90 ± 26.27   −9.60 (−19.9, 0.7)                                       69.70 ± 21.60   −11.52 (−24.2, 1.1)                                      66.67 ± 29.33   −7.09 (−22.7, 8.5)
                           3m         73.18 ± 24.17   −3.47 (−10.3, 3.4)                                       77.43 ± 19.46   −3.43 (−12.2, 5.4)                                       69.54 ± 27.40   −2.97 (−13.2, 7.3)
                           6m         74.13 ± 26.54   ref.                                                     77.94 ± 31.86   ref.                                                     69.81 ± 19.04   ref.
  Emotional function       Baseline   68.10 ± 23.83   −7.98[^\*^](#table-4fn1){ref-type="fn"}(−13.6, −2.4)     66.36 ± 25.99   −9.72[^\*^](#table-4fn1){ref-type="fn"}(−19.2, −0.2)     69.37 ± 22.40   −6.39[^\*^](#table-4fn1){ref-type="fn"}(−12.4, −0.4)
                           1m         77.78 ± 18.53   2.24 (−2.3, 6.8)                                         76.52 ± 19.69   1.55 (−5.9, 9.0)                                         78.65 ± 17.95   3.05 (−1.8, 7.9)
                           3m         75.45 ± 20.38   −0.67 (−4.2, 2.9)                                        75.58 ± 20.31   0.10 (−4.7, 4.9)                                         75.35 ± 20.81   −1.13 (−6.1, 3.8)
                           6m         75.17 ± 21.06   ref.                                                     76.14 ± 25.18   ref.                                                     74.07 ± 15.96   ref.
  Cognitive function       Baseline   74.22 ± 21.81   −5.75 (−12.2, 0.7)                                       72.22 ± 21.68   −9.57 (−19.9, 0.7)                                       75.68 ± 22.08   −1.83 (−8.8, 5.1)
                           1m         81.48 ± 17.03   2.17 (−3.8, 8.1)                                         79.55 ± 19.88   −0.73 (−10.6, 9.2)                                       82.81 ± 14.96   5.47 (−1.1, 12.1)
                           3m         80.34 ± 19.05   0.14 (−3.7, 4.0)                                         81.25 ± 19.37   −0.18 (−4.9, 4.5)                                        79.56 ± 19.08   1.28 (−4.4, 7.0)
                           6m         78.65 ± 19.96   ref.                                                     81.54 ± 22.48   ref.                                                     75.37 ± 16.83   ref.
  Social function          Baseline   48.96 ± 28.77   −20.08[^\*^](#table-4fn1){ref-type="fn"}(−28.6, −11.6)   53.70 ± 27.48   −20.36[^\*^](#table-4fn1){ref-type="fn"}(−32.8, −8.0)    45.50 ± 29.57   −18.84[^\*^](#table-4fn1){ref-type="fn"}(−30.2, −7.5)
                           1m         64.20 ± 22.06   −4.73 (−11.7, 2.2)                                       65.15 ± 21.15   −8.33 (−19.3, 2.6)                                       63.54 ± 22.97   −1.11 (−9.3, 7.1)
                           3m         69.71 ± 23.62   0.40 (−5.0, 5.8)                                         74.19 ± 19.94   0.67 (−6.3, 7.6)                                         65.87 ± 26.11   0.77 (−7.3, 8.8)
                           6m         69.79 ± 22.74   ref.                                                     73.86 ± 25.14   ref.                                                     65.19 ± 19.50   ref.
  Fatigue                  Baseline   42.48 ± 25.24   18.78[^\*^](#table-4fn1){ref-type="fn"}(11.1, 26.4)      43.21 ± 24.33   22.45[^\*^](#table-4fn1){ref-type="fn"}(10.4, 34.5)      41.96 ± 26.18   14.96[^\*^](#table-4fn1){ref-type="fn"}(5.8, 24.1)
                           1m         30.04 ± 15.21   6.20[^\*^](#table-4fn1){ref-type="fn"}(0.2, 12.2)        31.31 ± 16.31   10.32[^\*^](#table-4fn1){ref-type="fn"}(1.9, 18.7)       29.17 ± 14.60   2.06 (−5.8, 9.9)
                           3m         28.45 ± 18.23   5.11[^\*^](#table-4fn1){ref-type="fn"}(0.5, 9.7)         25.31 ± 20.42   4.23 (−0.2, 8.6)                                         31.15 ± 15.99   5.13 (−2.8, 13.1)
                           6m         24.48 ± 21.18   ref.                                                     21.57 ± 25.26   ref.                                                     27.78 ± 15.57   ref.
  Nausea/vomiting          Baseline   13.85 ± 19.22   8.04[^\*^](#table-4fn1){ref-type="fn"}(2.4, 13.7)        14.81 ± 22.33   9.23[^\*^](#table-4fn1){ref-type="fn"}(0.7, 17.8)        13.16 ± 16.96   7.96[^\*^](#table-4fn1){ref-type="fn"}(0.3, 15.7)
                           1m         8.33 ± 18.24    2.38 (−2.5, 7.3)                                         2.27 ± 7.79     −3.64 (−9.1, 1.8)                                        12.50 ± 22.00   7.32[^\*^](#table-4fn1){ref-type="fn"}(0.3, 14.3)
                           3m         10.31 ± 14.01   4.92[^\*^](#table-4fn1){ref-type="fn"}(0.5, 9.3)         5.32 ± 12.09    0.09 (−6.2, 6.4)                                         14.58 ± 14.32   9.72[^\*^](#table-4fn1){ref-type="fn"}(4.3, 15.2)
                           6m         5.64 ± 11.41    ref.                                                     4.74 ± 12.02    ref.                                                     6.67 ± 11.00    ref.
  Pain                     Baseline   44.87 ± 26.01   22.48[^\*^](#table-4fn1){ref-type="fn"}(14.0, 31.0)      45.68 ± 20.46   26.15[^\*^](#table-4fn1){ref-type="fn"}(13.9, 38.4)      44.30 ± 29.58   18.55[^\*^](#table-4fn1){ref-type="fn"}(7.5, 29.6)
                           1m         24.38 ± 19.88   1.92 (−4.9, 8.7)                                         27.27 ± 18.93   7.89 (−0.6, 16.3)                                        22.40 ± 20.57   −3.58 (−12.6, 5.5)
                           3m         28.21 ± 20.03   5.63[^\*^](#table-4fn1){ref-type="fn"}(0.2, 11.1)        25.12 ± 20.84   4.66 (−1.8, 11.1)                                        30.85 ± 19.28   5.62 (−3.0, 14.2)
                           6m         22.05 ± 21.40   ref.                                                     19.93 ± 24.93   ref.                                                     24.44 ± 17.10   ref.
  Dyspnea                  Baseline   23.44 ± 28.28   12.73[^\*^](#table-4fn1){ref-type="fn"}(4.7, 20.8)       20.99 ± 20.98   13.55[^\*^](#table-4fn1){ref-type="fn"}(3.4, 23.6)       25.23 ± 32.78   13.76[^\*^](#table-4fn1){ref-type="fn"}(1.3, 26.2)
                           1m         8.64 ± 17.36    −1.73 (−6.5, 3.1)                                        7.58 ± 17.61    −0.10 (−3.0, 2.8)                                        9.38 ± 17.42    −1.70 (−9.8, 6.4)
                           3m         13.46 ± 14.98   2.70 (−2.5, 7.9)                                         8.80 ± 13.50    0.70 (−5.5, 6.9)                                         17.46 ± 15.25   5.61 (−1.9, 13.1)
                           6m         10.94 ± 17.25   ref.                                                     7.84 ± 18.74    ref.                                                     14.44 ± 15.26   ref.
  Insomnia                 Baseline   48.21 ± 32.82   24.28[^\*^](#table-4fn1){ref-type="fn"}(14.5, 34.1)      46.91 ± 33.66   27.14[^\*^](#table-4fn1){ref-type="fn"}(12.9, 41.3)      49.12 ± 32.64   20.26[^\*^](#table-4fn1){ref-type="fn"}(6.4, 34.1)
                           1m         29.63 ± 27.98   4.39 (−3.7, 12.5)                                        36.36 ± 30.70   14.98[^\*^](#table-4fn1){ref-type="fn"}(4.9, 25.0)       25.00 ± 25.40   −4.98 (−17.4, 7.4)
                           3m         28.21 ± 23.75   4.53 (−1.6, 10.7)                                        25.93 ± 21.34   6.84[^\*^](#table-4fn1){ref-type="fn"}(0.2, 13.5)        30.16 ± 25.86   1.34 (−8.8, 11.5)
                           6m         25.35 ± 27.83   ref.                                                     18.95 ± 23.41   ref.                                                     32.59 ± 31.35   ref.
  Loss of appetite         Baseline   25.13 ± 30.64   10.00[^\*^](#table-4fn1){ref-type="fn"}(0.2, 19.8)       28.40 ± 32.95   20.59[^\*^](#table-4fn1){ref-type="fn"}(8.7, 32.4)       22.81 ± 29.11   −0.32 (−15.5, 14.8)
                           1m         13.58 ± 21.98   −1.91 (−9.4, 5.5)                                        10.61 ± 18.93   2.36 (−3.6, 8.4)                                         15.63 ± 23.92   −7.88 (−21.6, 5.8)
                           3m         20.09 ± 19.96   5.26 (−1.7, 12.2)                                        14.35 ± 17.49   6.68[^\*^](#table-4fn1){ref-type="fn"}(0.4, 13.0)        25.00 ± 20.92   2.37 (−10.5, 15.2)
                           6m         15.63 ± 23.59   ref.                                                     8.17 ± 14.84    ref.                                                     24.07 ± 28.92   ref.
  Constipation             Baseline   20.00 ± 26.87   1.72 (−6.1, 9.6)                                         18.52 ± 28.24   3.03 (−4.3, 10.3)                                        21.05 ± 26.19   −0.02 (−14.3, 14.3)
                           1m         16.05 ± 23.11   −3.31 (−10.2, 3.6)                                       13.64 ± 24.47   −2.43 (−7.8, 3.0)                                        17.71 ± 22.38   −4.47 (−17.7, 8.8)
                           3m         19.23 ± 21.88   1.73 (−3.3, 6.8)                                         14.12 ± 19.45   1.19 (−3.8, 6.2)                                         23.61 ± 23.21   2.16 (−7.2, 11.6)
                           6m         17.53 ± 25.05   ref.                                                     14.38 ± 22.74   ref.                                                     21.11 ± 27.79   ref.
  Diarrhea                 Baseline   22.40 ± 23.80   7.65[^\*^](#table-4fn1){ref-type="fn"}(0.6, 14.7)        27.16 ± 26.21   15.58[^\*^](#table-4fn1){ref-type="fn"}(6.2, 25.0)       18.92 ± 21.57   −0.61 (−10.6, 9.4)
                           1m         17.90 ± 19.11   3.55 (−2.4, 9.5)                                         19.70 ± 19.68   8.67[^\*^](#table-4fn1){ref-type="fn"}(1.0, 16.3)        16.67 ± 18.93   −2.64 (−10.7, 5.4)
                           3m         11.75 ± 15.39   −2.83 (−7.8, 2.2)                                        12.27 ± 17.34   0.57 (−5.4, 6.6)                                         11.31 ± 13.82   −7.72[^\*^](#table-4fn1){ref-type="fn"}(−15.2, −0.2)
                           6m         13.89 ± 15.90   ref.                                                     8.50 ± 14.45    ref.                                                     20.00 ± 15.69   ref.
  Financial problems       Baseline   42.71 ± 29.97   11.54[^\*^](#table-4fn1){ref-type="fn"}(1.0, 22.0)       35.80 ± 29.13   14.73[^\*^](#table-4fn1){ref-type="fn"}(1.1, 28.4)       47.75 ± 29.96   8.10 (−7.9, 24.1)
                           1m         32.72 ± 30.02   0.64 (−8.9, 10.2)                                        21.21 ± 24.22   −0.38 (−9.9, 9.2)                                        40.63 ± 31.38   0.09 (−16.3, 16.5)
                           3m         25.21 ± 26.00   −6.03 (−12.4, 0.4)                                       18.06 ± 23.81   −3.60 (−11.5, 4.3)                                       31.35 ± 26.63   −8.72 (−19.1, 1.7)
                           6m         30.56 ± 31.80   ref.                                                     23.53 ± 31.21   ref.                                                     38.52 ± 31.60   ref.

**Notes.**

*p* \< 0.05.

ref, reference group (the base for comparison).

Oral health outcomes
--------------------

At the baseline, a nasogastric (NG) tube was placed for all participants. One month after the operation, 18% persisted with NG tube feeding, 14% returned to normal diet, 28% and 40% started to get nutrition with a liquid and a soft diet, respectively. At six months, all NG tubes had been removed, and 53% returned to normal diet. 16% and 31% participants were able to orally intake a liquid and a soft diet.

IID and MMO had high positive correlation (*r* = .883). The mean IID was 22.5 ± 9.2 millimeters and significantly progressed to 31.8 ± 11.8 millimeters (*p* \< .001) in the overall model. The mean MMO was 22.6 ± 2.1 millimeters (baseline) and 31.8 ± 10.1 millimeters (6 months), which was also a statistically significant difference (*p* \< .001). In the group model, IID and MMO for both early stage and advanced stage groups significantly increased at 6 months compared to baseline, one and three months, individually as well. In the early stage group, IID increased from 21.8 ± 7.9 (baseline) to 34.0 ± 13.7 (six months) (*p* \< .001), and it increased from 23.1 ± 10.1 (baseline) to 29.1 ± 8.6 (six months) (*p* = .010) in the advanced stage group.

Health related quality of life and physical functions
-----------------------------------------------------

[Table 4](#table-4){ref-type="table"} illustrates the results of the EORTC QLQ-C30 scales. After six months of intensive physical therapy, health-related quality of life was significantly different (*p* \< .05) from the baseline on the global health scale and all functional scales, except cognitive function. The symptom scales of fatigue, nausea/vomiting, pain, dyspnea and insomnia showed significant differences between the baseline and six-month scores or between three-month and 6-month scores (*p* \< .05) for the overall and group models. However, no significant difference was found on the scales of constipation over time throughout the six months. While the scales of loss of appetite, diarrhea, and financial problems showed significantly high scores (*p* \< .05) at baseline compared with 6-month scores in the early stage group, it maintained at similar level over time throughout the 6 months in the advanced stage group.

[Table 5](#table-5){ref-type="table"} illustrates the results from the EORTC QLQ-H&N35 scales. All other symptom scales showed a significant difference (*p* \< .05) between the six-month test scores and the baseline scores in overall model and group model except on the scale on senses (tastes, smell) which showed no significant difference over six months in the early stage group. Oral pain, swallowing, and speech scores on the three-month test were significantly different (*p* \< .05) compared with those on the six-month test in the advanced group. The single item scales of opening mouth, dry mouth, sticky saliva and coughing showed significant differences between the baseline and six-month scores, and between 3-month and 6-month scores (*p* \< .05) except for the score on teeth and sexuality, which maintained at the same level over the 6 months in the early stage group and the advanced group.
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###### Overview of the EORTC QLQ-H&N35 scores in the whole model and group model.

![](peerj-06-4419-g009)

                              Overall model   Group model                                                                                                                                  
  ---------------- ---------- --------------- ----------------------------------------------------- ---------------- ----------------------------------------------------- --------------- --------------------------------------------------------
  Oral pain        Baseline   41.28 ± 27.03   19.90[^\*^](#table-5fn1){ref-type="fn"}(12.9, 26.9)   44.44 ± 24.02    24.18[^\*^](#table-5fn1){ref-type="fn"}(14.6, 33.8)   38.96 ± 29.14   15.80[^\*^](#table-5fn1){ref-type="fn"}(6.6, 25.0)
                   1m         23.15 ± 14.27   1.80 (−3.0, 6.6)                                      25.76 ± 13.83    5.75 (−1.3, 12.8)                                     21.35 ± 14.50   −1.90 (−7.0, 3.2)
                   3m         28.39 ± 18.29   6.43[^\*^](#table-5fn1){ref-type="fn"}(1.9, 11.0)     22.28 ± 16.72    1.72 (−4.7, 8.2)                                      33.63 ± 18.22   9.98[^\*^](#table-5fn1){ref-type="fn"}(4.8, 15.2)
                   6m         19.71 ± 15.54   ref.                                                  18.06 ± 19.02    ref.                                                  21.73 ± 10.20   ref.
  Swallowing       Baseline   56.21 ± 28.19   32.34[^\*^](#table-5fn1){ref-type="fn"}(25.4, 39.3)   46.60 ± 23.91    28.12[^\*^](#table-5fn1){ref-type="fn"}(18.2, 38.0)   63.21 ± 29.29   34.95[^\*^](#table-5fn1){ref-type="fn"}(25.7, 44.2)
                   1m         27.47 ± 19.67   4.19 (−1.0, 9.4)                                      26.14 ± 17.12    8.45[^\*^](#table-5fn1){ref-type="fn"}(2.5, 14.4)     28.39 ± 21.47   0.67 (−6.4, 7.8)
                   3m         32.48 ± 22.87   8.21[^\*^](#table-5fn1){ref-type="fn"}(3.1, 13.3)     22.11 ± 17.09    2.43 (−2.6, 7.5)                                      41.37 ± 23.69   12.91[^\*^](#table-5fn1){ref-type="fn"}(5.0, 20.8)
                   6m         24.60 ± 18.54   ref.                                                  20.18 ± 21.15    ref.                                                  29.96 ± 13.64   ref.
  Senses           Baseline   27.34 ± 31.90   9.02[^\*^](#table-5fn1){ref-type="fn"}(0.7, 17.4)     22.84 ± 28.17    9.28 (−2.5, 21.0)                                     30.63 ± 34.36   8.56 (−3.9, 21.0)
                   1m         13.58 ± 19.17   −4.44 (−11.4, 2.5)                                    11.36 ± 19.51    −2.86 (−11.5, 5.8)                                    15.10 ± 19.10   −5.58 (−17.0, 5.8)
                   3m         25.53 ± 21.61   6.97[^\*^](#table-5fn1){ref-type="fn"}(0.8, 13.2)     15.86 ± 15.44    2.47 (−4.6, 9.5)                                      33.83 ± 22.89   10.71[^\*^](#table-5fn1){ref-type="fn"}(0.4, 21.0)
                   6m         18.10 ± 23.97   ref.                                                  13.07 ± 20.43    ref.                                                  24.21 ± 27.18   ref.
  Speech           Baseline   52.43 ± 30.70   25.93[^\*^](#table-5fn1){ref-type="fn"}(17.1, 34.8)   48.56 ± 26.36    26.36[^\*^](#table-5fn1){ref-type="fn"}(13.2, 39.5)   55.26 ± 33.59   24.72[^\*^](#table-5fn1){ref-type="fn"}(13.0, 36.4)
                   1m         29.42 ± 20.83   4.18 (−2.3, 10.7)                                     31.31 ± 20.75    9.26[^\*^](#table-5fn1){ref-type="fn"}(0.7, 17.8)     28.13 ± 21.12   −0.20 (−9.0, 8.6)
                   3m         33.26 ± 25.06   6.21[^\*^](#table-5fn1){ref-type="fn"}(0.6, 11.8)     25.39 ± 17.42    2.62 (−4.8, 10.1)                                     40.01 ± 28.73   8.81[^\*^](#table-5fn1){ref-type="fn"}(1.0, 16.6)
                   6m         26.58 ± 24.30   ref.                                                  22.66 ± 25.45    ref.                                                  31.35 ± 22.81   ref.
  Social eating    Baseline   50.39 ± 32.71   14.08[^\*^](#table-5fn1){ref-type="fn"}(5.8, 22.4)    47.84 ± 32.08    15.97[^\*^](#table-5fn1){ref-type="fn"}(2.9, 29.1)    52.25 ± 33.49   11.87[^\*^](#table-5fn1){ref-type="fn"}(2.3, 21.4)
                   1m         33.33 ± 26.35   −2.33 (−8.5, 3.8)                                     35.23 ± 29.87    1.22 (−6.8, 9.2)                                      32.03 ± 24.05   −6.01 (−14.1, 2.1)
                   3m         37.34 ± 27.16   1.47 (−3.2, 6.1)                                      32.99 ± 24.83    −0.19 (−6.3, 5.9)                                     41.07 ± 28.93   2.26 (−4.3, 8.8)
                   6m         36.51 ± 24.37   ref.                                                  33.50 ± 30.21    ref.                                                  40.18 ± 14.85   ref.
  Social contact   Baseline   43.44 ± 29.07   14.93[^\*^](#table-5fn1){ref-type="fn"}(6.3, 23.5)    39.26 ± 24.34    14.95[^\*^](#table-5fn1){ref-type="fn"}(2.7, 27.2)    46.49 ± 32.07   14.62[^\*^](#table-5fn1){ref-type="fn"}(2.7, 26.5)
                   1m         28.40 ± 22.40   −0.68 (−7.2, 5.8)                                     30.00 ± 23.44    3.49 (−5.5, 12.5)                                     27.29 ± 21.97   −4.10 (−13.2, 5.0)
                   3m         30.67 ± 24.38   2.67 (−3.5, 8.8)                                      27.38 ± 21.67    3.11 (−4.4, 10.6)                                     33.49 ± 26.55   2.25 (−7.4, 11.9)
                   6m         28.61 ± 20.88   ref.                                                  26.40 ± 22.38    ref.                                                  30.72 ± 19.62   ref.
  Sexuality        Baseline   39.32 ± 35.68   12.24[^\*^](#table-5fn1){ref-type="fn"}(3.2, 21.3)    34.57 ± 27.71    12.26 (−0.5, 25.0)                                    42.79 ± 40.55   10.85 (−1.5, 23.2)
                   1m         29.94 ± 26.77   2.10 (−6.1, 10.3)                                     31.06 ± 26.38    6.24 (−2.3, 14.7)                                     29.17 ± 27.44   −2.52 (−15.4, 10.4)
                   3m         33.07 ± 29.03   5.77 (−0.2, 11.7)                                     28.01 ± 26.58    4.73 (−3.0, 12.5)                                     37.40 ± 30.79   5.51 (−3.6, 14.6)
                   6m         29.57 ± 29.65   ref.                                                  24.02 ± 33.58    ref.                                                  36.31 ± 23.48   ref.
  Teeth            Baseline   46.03 ± 36.13   5.86 (−5.8, 17.5)                                     41.98 ± 30.09    5.75 (−8.0, 19.5)                                     49.07 ± 40.23   5.33 (−13.5, 24.2)
                   1m         37.65 ± 32.41   −2.85 (−13.0, 7.3)                                    42.42 ± 31.17    5.86 (−5.6, 17.3)                                     34.38 ± 33.32   −9.75 (−26.2, 6.7)
                   3m         40.71 ± 26.83   −0.47 (−8.8, 7.9)                                     33.33 ± 24.08    −5.34 (−14.2, 3.6)                                    47.02 ± 27.86   3.22 (−11.2, 17.6)
                   6m         43.37 ± 33.62   ref.                                                  40.52 ± 34.79    ref.                                                  46.83 ± 33.10   ref.
  Opening mouth    Baseline   51.56 ± 34.60   20.97[^\*^](#table-5fn1){ref-type="fn"}(12.0, 29.9)   48.15 ± 32.47    25.05[^\*^](#table-5fn1){ref-type="fn"}(12.1, 38.0)   54.05 ± 36.30   14.51[^\*^](#table-5fn1){ref-type="fn"}(3.2, 25.8)
                   1m         37.04 ± 30.83   6.69 (−1.7, 15.1)                                     40.91 ± 32.42    18.96[^\*^](#table-5fn1){ref-type="fn"}(7.6, 30.3)    34.38 ± 29.92   −5.52 (−15.6, 4.5)
                   3m         36.43 ± 24.64   4.94 (−1.1, 10.9)                                     34.03 ± 23.07    9.05[^\*^](#table-5fn1){ref-type="fn"}(1.6, 16.5)     38.49 ± 26.14   −1.15 (−9.5, 7.3)
                   6m         32.08 ± 27.51   ref.                                                  23.86 ± 26.99    ref.                                                  42.06 ± 25.57   ref.
  Dry mouth        Baseline   42.71 ± 29.97   4.93 (−6.6, 16.4)                                     44.44 ± 30.66    18.64[^\*^](#table-5fn1){ref-type="fn"}(4.3, 33.0)    41.44 ± 29.82   −10.77 (−25.0, 3.5)
                   1m         31.48 ± 22.82   −6.51 (−17.4, 4.4)                                    37.88 ± 23.67    12.10 (−2.0, 26.2)                                    27.08 ± 21.48   −25.49[^\*^](#table-5fn1){ref-type="fn"}(−37.1, −13.9)
                   3m         39.85 ± 23.54   1.04 (−6.7, 8.8)                                      33.33 ± 21.17    6.14 (−2.7, 15.0)                                     45.44 ± 24.38   −7.35 (−18.8, 4.1)
                   6m         39.61 ± 32.10   ref.                                                  28.43 ± 33.79    ref.                                                  53.17 ± 24.72   ref.
  Sticky saliva    Baseline   50.52 ± 35.13   18.25[^\*^](#table-5fn1){ref-type="fn"}(7.0, 29.5)    49.38 ± 36.25    21.47[^\*^](#table-5fn1){ref-type="fn"}(6.7, 36.3)    51.35 ± 34.78   15.50 (−1.2, 32.2)
                   1m         30.86 ± 23.21   −1.24 (−11.5, 9.1)                                    27.27 ± 19.62    −0.49 (−14.1, 13.1)                                   33.33 ± 25.40   −2.33 (−17.6, 12.9)
                   3m         40.71 ± 27.65   8.32[^\*^](#table-5fn1){ref-type="fn"}(0.0, 16.6)     28.47 ± 24.37    −0.21 (−9.3, 8.9)                                     51.19 ± 26.29   15.50[^\*^](#table-5fn1){ref-type="fn"}(2.4, 28.6)
                   6m         31.72 ± 29.99   ref.                                                  28.76 ± 32.65    ref.                                                  35.32 ± 27.18   ref.
  Coughing         Baseline   46.88 ± 27.68   25.39[^\*^](#table-5fn1){ref-type="fn"}(17.7, 33.1)   39.51 ± 22.72    25.07[^\*^](#table-5fn1){ref-type="fn"}(13.8, 36.4)   52.25 ± 29.96   24.25[^\*^](#table-5fn1){ref-type="fn"}(14.7, 33.8)
                   1m         25.93 ± 24.80   4.58 (−2.3, 11.4)                                     21.21 ± 16.41    6.55 (−3.5, 16.6)                                     29.17 ± 29.02   1.73 (−5.8, 9.3)
                   3m         30.45 ± 21.09   9.38[^\*^](#table-5fn1){ref-type="fn"}(3.8, 15.0)     22.92 ± 15.40    8.38[^\*^](#table-5fn1){ref-type="fn"}(1.1, 15.7)     36.90 ± 23.34   9.45[^\*^](#table-5fn1){ref-type="fn"}(1.4, 17.5)
                   6m         19.18 ± 16.22   ref.                                                  13.73 ± 16.91    ref.                                                  25.79 ± 13.00   ref.
  Feeling ill      Baseline   57.81 ± 92.44   28.78[^\*^](#table-5fn1){ref-type="fn"}(6.9, 50.6)    71.60 ± 136.41   41.73 (−7.8, 91.3)                                    47.75 ± 35.61   21.61[^\*^](#table-5fn1){ref-type="fn"}(9.9, 33.4)
                   1m         26.54 ± 25.39   −1.45 (−8.6, 5.7)                                     31.82 ± 26.18    3.26 (−6.6, 13.2)                                     22.92 ± 24.59   −2.32 (−12.1, 7.4)
                   3m         34.62 ± 22.32   5.09 (−1.1, 11.3)                                     32.41 ± 20.96    2.12 (−5.4, 9.6)                                      36.51 ± 23.64   9.86[^\*^](#table-5fn1){ref-type="fn"}(0.9, 18.8)
                   6m         29.03 ± 20.47   ref.                                                  29.08 ± 27.18    ref.                                                  28.97 ± 7.60    ref.

**Notes.**

*p* \< 0.05.

ref., reference group (the base for comparison).

At three-months and six-months, 6MWD was 339.0 ± 54.4m and 381.2 ± 69.9m, respectively (*p* \< .001). TUG was 10.6 ± 2.4 s at 3 months and 8.4 ± 1.5 s at 6-months (*p* \< .001). 6MWD on the 3-month and 6-month tests, respectively, was 355.5 ± 55.9m and 396.5 ± 73.5m (*p* = .029) in the early stage group, and 321.6 ± 48.2m and 363.1 ± 64.0m in the advanced stage group (*p* = .003). No significant difference was found between groups at 3 or 6 months on either measure.

Our analysis found a predicted return-to-work rate of 34.7% at three months, 63.0% at the six months and 80% at one year after surgery, respectively. The log rank test showed the time of return-to-work was significantly different between the early stage group and the advanced stage (*p* = .032). In the early stage group, it predicted that about 80% would return to work one year after the operation, but around 50% would return to work in the advanced stage group ([Fig. 4](#fig-4){ref-type="fig"}). Further analysis showed 71.4% return-to-work rate in the retired or unemployed, 86.7% in the self-employed, 80% in the professional, 33.3% in the administration, 81.8% in the service and 87.5% in the semi-skilled or skilled according to vocational type.

![Curve of the percentage of return-to-work patients at post-operative month in the early and advanced stage groups.](peerj-06-4419-g004){#fig-4}

Discussion
==========

In this single-arm pilot study we investigated early physical therapy interventions designed to improve active shoulder abduction and muscle strength surrounding the scapula. Shoulder functions including joint ROM, MMT, pain and DASH in the initial six- month post-operation were measured. In the early phase, the average shoulder ROM was limited to less than one-third the normal range, after which shoulder abduction had significantly improved at six-months post-surgery. In the model analyzed by the GEE procedure, the strength of the muscle group responsible for scapular stabilization, consisting of the trapezius, serratus anterior, and rhomboid, significantly improved during the six months. Furthermore, the deltoid and supraspinatus muscle also showed improvements in this study. Average shoulder pain measured by VAS did not exceed 2 at the baseline and the following six months. The DASH outcome measure reached MCID at the one-month evaluation, and maintained up to six months after the operation.

Ewing and Martin found shoulder problems after neck dissection with a clinical picture that included drooping of the shoulder, limited forward flexion, lateral abduction and rotation of the shoulder and reduced EMG activity ([@ref-15]). EMG studies also showed that trapezius muscle activity decreased after neck dissection ([@ref-20]; [@ref-27]; [@ref-32]). In our study, shoulder ROM and upper trapezius strength almost fully recovered during the early stage of physical therapy intervention, and scapular muscle strength showed continuous progress throughout the 6-month study period after the operation. PRE training has been found to improve shoulder function compared with standard intervention following neck dissection in randomized controlled trials ([@ref-29]; [@ref-30]). The timing of the physical therapy intervention in these previous studies was categorized into early and late stages. Early intervention seems to have some positive impact on this diagnostic group of patients and its change persisted for the entire six months of observation.

In previous studies, the target muscles included the upper trapezius ignoring the lower trapezius. An interesting finding of this study is that the upper trapezius gained normal level of strength soon after one month of intervention, but the middle and lower trapezius did not show a return to normal levels until after six months of intervention. In our model, the VAS and DASH scores showed mild disturbance at six months after surgery. This may be related to the impaired middle and lower trapezius, and needs further study in the future. In the reviewed articles, support of the beneficial effect of physical therapy for ANSD following neck dissection lacks convincing evidence ([@ref-5]; [@ref-8]; [@ref-26]). In recent studies, PRE was introduced for the target muscles acting as scapular stabilizers (the upper trapezius, middle trapezius, rhomboid major, and serratus anterior muscle) rather than for the muscles surrounding the glenohumeral joint ([@ref-20]; [@ref-27]; [@ref-28]). Improvements were observed in scapular muscles receiving PRE within six months after the operation. We suggest that lower trapezius muscle strengthening should be considered in the ANSD population.

TMJ ROM was measured by IID and MMO in this study. Our participants started to exercise their TMJ once the wound was stable, at an average of 8.3-days post-operation. Briefly speaking, our strategy was to promote early mobilization of the TMJ. The results showed a near 10 mm increase in TMJ ROM in six months. In the group model, the potential was more obvious in the early stage group. Early intervention to exercise the TMJ, may improve mouth opening. In the advanced stage group, the maximum mouth opening reached its highest at three months. This phenomenon may be related to RT. In our series, a higher rate of patients needed to receive RT among the advanced stage patients, which is consistent with other studies ([@ref-42]). We measured MMO by the method described by [@ref-25]. This method can overcome the issue of missing teeth, and was highly correlated with the distance between incisors measured by a Willis gauge after our analysis.

We tested 6MWD to evaluate the prognosis of functional capacity and lower extremity function. [@ref-3] systematically reviewed fifteen articles and concluded that 6MWD has strong evidence in support of its use to evaluate clinical change following cardiac rehabilitation 6MWD is significantly correlated with peak aerobic capacity (VO2peak). It is considered the gold standard outcome and is easily accessible in clinical practice ([@ref-36]). Our results showed that 6MWD significantly improved between the 3- and 6-month evaluations in both the overall and the group model. In Liu's study, they performed the 6MWD test before and after 3 months of home-based exercise to evaluate lower extremity function after fibula osteocutaneous flap reconstruction for mandibular defects in oral cancer patients ([@ref-21]). Their results showed no significant difference in the walking distance. The exercise intervention was almost 1 year after surgery. In our series, the donor sites were harvested mostly from the lower extremity. The total walking distance and timed up and go (TUG) scores increased significantly in the first three months in both the overall and group model. Improved functional capacity and mobility may have been a factor contributing to early return-to-work. Return to work in many cancer survivors is a realistic outcome. Further study of the effect of rehabilitation on functional restoration and quality of life for oral cancer survivors is needed. In this study, our results suggested that early intervention and good compliance might help 80% of oral cancer survivors return to work within one year post-operation. We found a significant difference in the group model indicating that the cohort of early stage survivors returned faster and had a higher rate of return than the cohort of advanced stage survivors. In addition, return-to-work rate differs in different vocational types, with a higher rate of return in the skilled or semi-skilled and self-employed. In this study, samples are small in number in varied vocational types, further statistical analysis would convey little information. However, this would be an issue worth further investigation.

In this six-month goal-oriented rehabilitation program for the population of oral cancer survivors, the health-related QoL were observed to improve. In the domains measured by the EORTC QLQ-C30 scales and EORTC QLQ-H&N35 scales, the global health and other functional scales, except for cognitive function, improved significantly in the first month. Global health and physical function continued to improve throughout the 6 months. In our comparison of the early stage group and the advanced stage group, we found that global health and physical function deteriorated at the three-month evaluation in the advanced stage survivors. In some of the symptom and single item scales the same trend was observed, with the participant self-ratings being the worst at three months. These items included oral pain, swallowing, senses, speech, sticky saliva, feeling ill, and global health. As these are common side effects of radiation, they received low self-ratings at post-operative month 3 may be explained by the onset of RT. This finding is consistent with other studies ([@ref-11]; [@ref-40]). We discovered that the progression of some self-rated scales might be different in the group model. For example, global health reached a relatively stable score by the third month in the early stage group, whereas the score decreased at the three-month evaluation compared to baseline and recovered to the level measured at post-operative month 1 in the advanced stage group by the six-month evaluation. Self-rated health is a cognitive process, which is affected by internal and external factors ([@ref-17]; [@ref-18]). We evaluated the outcomes of an early- and integrated-intervention program focused primarily on oral cavity function and secondarily on issues that result from the oncological and reconstructive surgery, and found significant improvement on several items within the six month study period.

The limitation of this study is the rather high loss rate up to 34%. In addition, follow-up lasted for only six months after surgery and the limited number of subjects recruited in this study. The shoulder pain and DASH scores still indicated mild impairment at the six-month evaluation. As a single-arm pilot study, tracking outcomes of subjects who had received oral cancer reconstruction surgery with early intervention rehabilitation program is our main objective. The results herein convey a possible application of early intervention to this diagnostic group of patients. The effect of early PRE intervention to the target muscles would be a worthwhile focus of future studies in this population. In addition, substantial outcomes were evaluated on limited number of subjects recruited in this study which might lead to a false-positive analytic results. An inclusion of a control group may warrant a better estimate of the effect of an early intervention to this group of patients as well.

Conclusion
==========

Our results showed that shoulder joint range of motion and muscle strength progressively improved during the six months of observation, as did oral function and global health. Though subjects in this study underwent a comprehensive intervention program lasting only six months, all showed continued improvements in oral, upper extremity and lower extremity functions, as well as recovery of social roles (return to work). We suggest an early and integrated intervention, and a follow-up of at least six months following reconstructive surgery for future studies and clinical trials for oral cancer survivors; however, with discretion toward patients receiving radiation therapy.
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